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A report on the Cancer Research UK London Research
Institute Special Conference ‘Signal Transduction’, London,
UK, 14-16 May 2007.
Disruption of intracellular signaling is central to many dif-
ferent diseases, including cancer. A conference on signaling
mechanisms held recently in London under the auspices of
the charity Cancer Research UK looked at cell-signaling
pathways in relation to cancer and how they may point to
new therapeutic approaches.
Signaling pathways and signaling mechanisms
The canonical Wnt/β-catenin pathway is implicated in both
normal development and disease. For example, APC, a com-
ponent of the canonical Wnt signaling pathway, was first iso-
lated as a tumor suppressor gene in human colon cancer and
activating mutations in β-catenin are found in human colon
cancer and melanomas. Two distinct receptors are required
for its activation: Frizzled, a seven-span receptor, and the
LDL-receptor related proteins 5 or 6 (LRP5 or LRP6). Xi He
(Children’s Hospital and Harvard Medical School, Boston,
USA) discussed the formation and activation of the Frizzled-
LRP5/6 receptor complex. Upon binding to Wnt ligands,
LRP6 is phosphorylated on serines (S) in multiple proline
(P)-rich PPPSPxS motifs, which is sufficient to activate the
pathway. He went on to describe how the two serines in
PPPSPxS are phosphorylated by two distinct kinases, casein
kinase 1 and glycogen synthase kinase 3 (Gsk3β). A role for
Gsk3β in the activation of the pathway was something of a
surprise, as its textbook role is to inhibit the pathway by pro-
moting  β-catenin phosphorylation and degradation. His
group has resolved the problem by showing that membrane-
associated Gsk3β activates Wnt signaling, whereas Gsk3β in
the cytosol has the opposite effect.
The Ras-activated MAP kinase (MAPK) module is part of
many signaling pathways, and RAS is one of the genes com-
monly found mutated in human cancers. The scaffold
protein KSRI (kinase supressor of Ras) is involved in the
positive regulation of the MAPK pathway. Upon Ras activa-
tion, KSRI translocates from the cytosol to become associ-
ated with the plasma membrane, where it interacts with the
three kinases of the MAPK pathway, Raf, MEK and ERK, to
facilitate their Ras-induced activation. Deborah Morrison
(National Cancer Institute, Frederick, USA) described a
search for proteins that associate with KSRI and might affect
Ras signaling, and the identification of one such protein,
casein kinase 2 (CK2), using mass spectrometry. She
reported that CK2 interacts with the basic surface of the C1
domain of KSRI, and that disruption of this interaction does
not interfere with growth-factor-stimulated KSRI membrane
association or its binding to MEK and ERK, but does reduce
levels of phosphorylation for two members of the mam-
malian Raf kinases, C-Raf and B-Raf. In vitro assays showed
that the negative-charge regulatory regions (N-regions) of
C-Raf and B-Raf are in fact substrates for CK2, suggesting
that CK2 acts as a Raf N-region kinase participating in the
KSRI complex and contributing to ERK activation.
Modeling and imaging of signaling pathways
Although hundreds of unique proteins are associated with
the regulation of cell shape, there is no systems-level under-
standing of the organization and composition of the signal-
ing pathways that affect them. Norbert Perrimon (Harvard
Medical School, Boston, USA) reported a high-content RNA
interference (RNAi) screen for signaling mediated by small
GTPases, which results in changes in cell shape. Hundreds of
pictures of treated cells are taken automatically and classi-
fied in a compendium of ‘quantitative morphological signa-
tures’. Using this information, genes were assigned to
distinct local signaling networks involved in mechanismsthat regulate cell adhesion, cell tension and cell protrusion,
and several signaling networks were identified as possible
regulators of particular morphological changes and behav-
iors. The new RNAi libraries include two to three double-
stranded RNAs per gene in two different concentrations; in
addition, subsets of RNAi libraries are now available, such as
‘the best annotated Drosophila melanogaster genes’ or ‘D.
melanogaster genes that are phylogenetically conserved with
mammalian genes’.
Olli Kallioniemi (Turku Centre for Biotechnology, Turku,
Finland) reported RNAi investigations of prostate cancer
development. Using libraries of 20,000 small interfering
RNAs, RNAi of living cancer cells identified genes essential
for the growth of androgen-independent prostate cancer
cells. He described a novel RNAi screening platform using
miniaturized arrays of 10,000 spots of 150-250 cells each,
which can be assessed for parameters such as cell numbers,
cell death, or cell cycle behavior. The technique has proved
efficient and reproducible, and is compatible with standard
analyses and commonly used scanners, microscopes and
imagers. Using this platform, breast cancer cell lines have
been screened by RNAi and the results combined with data
from tumors to reveal genes that are coexpressed in aggres-
sive breast cancers in vivo.
Live-cell imaging is a valuable tool to investigate the dynamics
of cellular processes. Discussing the development of biosen-
sors for imaging signaling and cell motility, Klaus Hahn
(University of North Carolina, Chapel Hill, USA) described a
method for monitoring the endogenous activity of the small
GTPase RhoA. The biosensor comprises the Rho-binding
domain of the small protein rhotekin covalently linked to
cyan fluorescent protein (CFP) and then covalently joined to
the amino terminus of full-length RhoA, itself linked to a
yellow fluorescent protein (YFP). In cells expressing the con-
struct, activation of RhoA leads to binding of the rhotekin
domain, which brings the two fluorescent proteins together
to produce a fluorescent resonance energy transfer (FRET)
signal. The construct does not interfere with the turnover of
the active and inactive state of RhoA or its membrane local-
ization. Hahn’s group has used this approach to monitor the
kinetics of the small GTPase Cdc42 and to assess the dynam-
ics of RhoA activity in fibroblasts during membrane protru-
sion as well as the interaction between RhoA and the
microtubule-associated GEF-H1 during cytokinesis.
Signaling pathways as therapeutic targets
The phosphatidylinositol-3-OH-kinase (PI3K) pathway is
involved in a wide variety of cellular functions, including cell
growth, differentiation and survival, glucose metabolism and
organization of the cytoskeleton. Dysregulation of this
kinase can lead to cancer, and much effort is being invested
in identifying components of this pathway as possible targets
for therapy. Because the known PI3K inhibitors, such as
wortmannin, inactivate all eight mammalian isoforms of
PI3K and are toxic, an alternative approach to examining its
role was proposed by Bart Vanhaesebroeck (Ludwig Insti-
tute for Cancer Research, London, UK). His group has gen-
erated kinase-inactive knock-in mice by introducing
mutations into the ATP-binding domain of the various class
1A PI3K genes, thus producing isoform-specific inhibition of
signaling without the use of drugs. Knock-in mice with a
non-functional PI3K catalytic subunit p110α die at embry-
onic stage E10.5 as a result of vascular defects. Knock-in
animals with a non-functional p110δ catalytic subunit, on
the other hand, are viable but show reduced immune
responses, a confirmation of the role of p110δ PI3K as a reg-
ulator of B-cell receptor signaling.
The intestine is a favorite system for studying epithelial stem
cells and their relation to cancer. Hans Clevers (Netherlands
Institute for Developmental Biology, Utrecht, The Nether-
lands) reported the discovery of a marker for intestinal stem
cells. GPR49 is a G-protein-coupled receptor that is a target
of the Wnt signaling pathway and is expressed in cancer
cells. In normal gut epithelium it is expressed in the colum-
nar epithelial cells in the base of the crypts. Clevers
described the generation of mice in which GPR49-express-
ing cells can be marked and their descendants traced for
several days. In these mice, the GPR49-expressing cells
could give rise to all the intestine and stomach epithelium,
indicating that GPR49 is a marker for intestinal stem cells.
Overacting mutations of GPR49 are implicated in colon
cancer, making GPR49 a potential target for colon cancer
therapy. Gaining insight on GPR49 function will help in
future treatments.
Richard Marais (Institute of Cancer Research, London, UK)
discussed the role of the protein kinase BRAF in melanomas.
BRAF is mutated in 70% of human melanomas, with a valine
to glutamic acid substitution at position 600 (V600E) being
the most common mutation; this elevates the kinase activity
of BRAF 500-fold. He described the generation of tamox-
ifen-inducible V600EBRAF mice and reported that six months
after the application of tamoxifen to the skin, these animals
develop melanomas, indicating that V600EBRAF is an initiat-
ing oncogene. The transcription factor MITF is critical for
normal melanocyte development and function, controlling
lineage commitment, proliferation, differentiation and sur-
vival, as well as melanin synthesis. Marais showed that in
melanoma cells, progression is ensured by the regulation of
MITF by BRAF, which involves both transcriptional and
post-translational mechanisms. Novel therapeutic approaches
to treating melanoma might be developed by targeting BRAF
signaling.
The p53 tumor suppressor protein is known as the gatekeeper
of genome integrity, directing cells that have suffered DNA
damage to undergo apoptosis. p53 is negatively controlled by
the protein MDM2, which modulates its transcriptional
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cancers, and thus inhibiting its interaction with p53 might
offer a novel therapeutic approach. To this end, Lyubomir
Vassilev (Hoffman-La Roche, Nutley, USA) described the
development of nutlins, small-molecule antagonists of the
p53-MDM2 interaction. Nutlins specifically interact with
MDM2 and free p53 from negative control. Nutlin-3, for
example, induces a senescent phenotype in apoptosis-resis-
tant cancer cell lines. Vassilev reported that nutlin-3 acti-
vates p53 and restores its cell-cycle arrest function in cell
lines derived from solid tumors of various types. Induction
of p53-directed apoptosis can also be affected by the protein
MDMX, which binds p53. Nutlin-3 does not inhibit p53-
MDMX complex formation, but MDM2 is upregulated.
MDM2 in turn mediates ubiquitin-dependent degradation of
MDMX, leading to destruction of its complex with p53 and
activation of apoptosis. Most important, Vassilev reported
that nutlin-3 has antitumor activity in vivo. Oral administra-
tion of nutlin-3 in mice with osteosarcomas or prostate
tumors results in reduction of tumor size.
Overall, the meeting highlighted the main avenues of basic
research on signal transduction, its relationship to tumori-
genesis and the development of new therapeutic approaches
and strategies for cancer treatment via targeting members of
signaling pathways. The 2008 LRI conference will focus on
chromosome biology.
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